• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BAFF/BLyS和APRIL与TNF家族受体BAFFR/BR3和BCMA结合的选择性。

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

作者信息

Day Eric S, Cachero Teresa G, Qian Fang, Sun Yaping, Wen Dingyi, Pelletier Marc, Hsu Yen-Ming, Whitty Adrian

机构信息

Department of Drug Discovery, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA.

出版信息

Biochemistry. 2005 Feb 15;44(6):1919-31. doi: 10.1021/bi048227k.

DOI:10.1021/bi048227k
PMID:15697217
Abstract

BAFF (B cell activating factor of the TNF family, also known as BlyS and TALL-1), a TNF family cytokine critical for the development and function of B cells, has been reported to bind to three receptors, BCMA (B cell maturation protein), TACI (transmembrane activator and CAML [calcium-modulator and cyclophilin ligand] interactor), and BAFFR (BAFF receptor), but with widely conflicting values for the affinity and selectivity of binding. BCMA and TACI additionally bind APRIL (a proliferation-inducing ligand), the TNF family ligand most homologous to BAFF. Using soluble, monomeric forms of the receptors, we demonstrate that BAFFR binds BAFF with K(D) approximately 16 nM, while BCMA binds with K(D) approximately 1.6 microM, indicating a approximately 100-fold selectivity for binding to BAFFR over BCMA. APRIL shows the opposite selectivity, binding to BCMA with K(D) approximately 16 nM while showing no detectable affinity for BAFFR (K(D) > 3 microM). The binding of BAFF or APRIL to these receptors is highly sensitive to assay-dependent avidity effects, likely explaining the widely ranging affinity values reported in the literature. Binding of BAFF to BCMA-Fc, a bivalent fusion protein consisting of the extracellular domain of BCMA fused to the hinge and CH1 and CH2 domains of human IgG1, in solution or coated onto an ELISA plate gave apparent binding affinities of approximately 0.63 and approximately 0.15 nM, respectively, compared to values of K(D(app)) <or= 30 and approximately 100 pM for the corresponding BAFFR/IgG1 fusion protein, BAFFR-Fc. The high selectivity of BAFF for BAFFR versus BCMA is thus partly obscured in these multivalent assays. The intrinsically high selectivity inferred from the measurements with monomeric receptor correlates well with in vivo data from knockout mice, providing a possible explanation for the observations that interruption of the BAFFR gene in the A/WySnJ mouse produces a phenotype similar to the BAFF knockout mouse, while the BCMA knockout mouse has no discernible B cell phenotype.

摘要

BAFF(肿瘤坏死因子家族的B细胞激活因子,也称为BlyS和TALL-1)是一种对B细胞的发育和功能至关重要的肿瘤坏死因子家族细胞因子,据报道它可与三种受体结合,即BCMA(B细胞成熟蛋白)、TACI(跨膜激活剂和CAML[钙调节蛋白和亲环素配体]相互作用分子)和BAFFR(BAFF受体),但关于结合亲和力和选择性的值差异很大。BCMA和TACI还可结合APRIL(增殖诱导配体),它是与BAFF同源性最高的肿瘤坏死因子家族配体。使用受体的可溶性单体形式,我们证明BAFFR与BAFF的结合解离常数(K(D))约为16 nM,而BCMA与BAFF的结合解离常数约为1.6 μM,这表明BAFF与BAFFR结合的选择性比与BCMA高约100倍。APRIL表现出相反的选择性,它与BCMA的结合解离常数约为16 nM,而对BAFFR无明显亲和力(K(D)>3 μM)。BAFF或APRIL与这些受体的结合对检测依赖性亲和力效应高度敏感,这可能解释了文献中报道的广泛的亲和力值差异。BAFF与BCMA-Fc(一种由BCMA的胞外结构域与人IgG1的铰链区、CH1和CH2结构域融合而成的二价融合蛋白)在溶液中或包被在ELISA板上的结合,其表观结合亲和力分别约为0.63和0.15 nM,而相应的BAFFR/IgG1融合蛋白BAFFR-Fc的K(D(app))≤30和约100 pM。因此,在这些多价检测中,BAFF对BAFFR相对于BCMA的高选择性部分被掩盖了。从单体受体测量中推断出的内在高选择性与敲除小鼠的体内数据相关性良好,这为以下观察结果提供了一种可能的解释:A/WySnJ小鼠中BAFFR基因的中断产生的表型与BAFF敲除小鼠相似,而BCMA敲除小鼠没有明显的B细胞表型。

相似文献

1
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.BAFF/BLyS和APRIL与TNF家族受体BAFFR/BR3和BCMA结合的选择性。
Biochemistry. 2005 Feb 15;44(6):1919-31. doi: 10.1021/bi048227k.
2
Identification of proteoglycans as the APRIL-specific binding partners.鉴定蛋白聚糖为APRIL特异性结合伴侣。
J Exp Med. 2005 May 2;201(9):1375-83. doi: 10.1084/jem.20042309. Epub 2005 Apr 25.
3
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site.BAFF/BLyS受体3包含一个最小的肿瘤坏死因子受体样模块,该模块编码一个高度专一的配体结合位点。
Biochemistry. 2003 May 27;42(20):5977-83. doi: 10.1021/bi034017g.
4
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF.BAFF-R,一种新发现的与BAFF特异性相互作用的肿瘤坏死因子受体。
Science. 2001 Sep 14;293(5537):2108-11. doi: 10.1126/science.1061965. Epub 2001 Aug 16.
5
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.与肿瘤坏死因子家族成员BAFF和APRIL结合的B细胞成熟蛋白对于体液免疫反应并非必需。
Mol Cell Biol. 2001 Jun;21(12):4067-74. doi: 10.1128/MCB.21.12.4067-4074.2001.
6
Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.脂肪细胞作为免疫细胞:在正常和病理性脂肪组织发育的不同阶段,肿瘤坏死因子样弱凋亡诱导因子(TWEAK)、B细胞活化因子(BAFF)和增殖诱导配体(APRIL)及其受体(Fn14、BAFF-R、跨膜激活剂和钙调亲环素配体相互作用分子(TACI)以及B细胞成熟抗原(BCMA))的差异表达
J Immunol. 2009 Nov 1;183(9):5948-56. doi: 10.4049/jimmunol.0901186. Epub 2009 Oct 14.
7
BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors.BAFF通过不同的受体支持淋巴滤泡中的人类B细胞分化。
Int Immunol. 2005 Jun;17(6):779-88. doi: 10.1093/intimm/dxh259. Epub 2005 May 20.
8
Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.合成的CpG寡脱氧核苷酸增强BAFF和APRIL介导的免疫球蛋白分泌。
Eur J Immunol. 2007 Jul;37(7):1785-95. doi: 10.1002/eji.200636800.
9
The uncertain glory of APRIL.四月的朦胧之美。
Cell Death Differ. 2003 Oct;10(10):1121-5. doi: 10.1038/sj.cdd.4401291.
10
Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes.细胞外人类BAFF的晶体结构,BAFF是一种刺激B淋巴细胞的肿瘤坏死因子家族成员。
J Mol Biol. 2002 Feb 1;315(5):1145-54. doi: 10.1006/jmbi.2001.5296.

引用本文的文献

1
Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation.替利西普治疗肾移植后复发性IgA肾病
Clin Kidney J. 2025 Jul 16;18(8):sfaf232. doi: 10.1093/ckj/sfaf232. eCollection 2025 Aug.
2
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma.多发性骨髓瘤中针对BCMA的双特异性抗体和CAR T细胞疗法的耐药机制
Cells. 2025 Jul 15;14(14):1077. doi: 10.3390/cells14141077.
3
The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances.
B细胞活化因子系统在自身免疫性疾病中的作用:机制、疾病影响及治疗进展
Front Immunol. 2025 Jun 6;16:1538555. doi: 10.3389/fimmu.2025.1538555. eCollection 2025.
4
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.过继性细胞免疫疗法的进展及多发性骨髓瘤的治疗突破。
Exp Hematol Oncol. 2024 Oct 28;13(1):105. doi: 10.1186/s40164-024-00576-6.
5
New Insights and Future Perspectives of APRIL in IgA Nephropathy.APRIL 在 IgA 肾病中的新见解和未来展望。
Int J Mol Sci. 2024 Sep 26;25(19):10340. doi: 10.3390/ijms251910340.
6
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.用于治疗复发/难治性多发性骨髓瘤的双特异性抗体
Cancers (Basel). 2024 Jun 26;16(13):2337. doi: 10.3390/cancers16132337.
7
Role of telitacicept in the treatment of IgA nephropathy.特利塞普特在 IgA 肾病治疗中的作用。
Eur J Med Res. 2023 Sep 22;28(1):369. doi: 10.1186/s40001-023-01320-2.
8
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.复发多发性骨髓瘤中靶向 BCMA 疗法的不良反应管理:聚焦综述
J Clin Med. 2023 Aug 25;12(17):5539. doi: 10.3390/jcm12175539.
9
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.靶向多发性骨髓瘤患者中的B细胞成熟抗原:当前观点
Onco Targets Ther. 2023 Jun 20;16:441-464. doi: 10.2147/OTT.S370880. eCollection 2023.
10
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses.通过单细胞分析了解人类骨髓浆细胞成熟和存活途径的异质性。
Cell Rep. 2023 Jul 25;42(7):112682. doi: 10.1016/j.celrep.2023.112682. Epub 2023 Jun 24.